跳至主要内容
临床试验/NCT05434533
NCT05434533已完成4 期

The Prophylactic Role of Tranexamic Acid in High Risk Pregnant Women Undergoing Elective Cesarean Section in Prevention of Postpartum Hemorrhage

Cairo University1 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2022年7月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
156
试验地点
1
主要终点
Reduction of blood loss during C-section.

研究概览

简要总结

The aim of the study is to assess the prophylactic role of tranexamic acid in reducing blood loss during and after elective cesarean section delivery in high risk patients.

Comparing effect of administration of 1gm of TXA half an hour before elective C-section , effect of administration of 1gm of TXA on the start of uterine incision and placebo effect, Where in all an addition of prophylactic uterotonics is given, in a randomized control, double blind trial of 3 groups.

详细描述

All patients will undergo the following

I. History : Medical history, Obstetric history, Comorbidities, Allergies. II. Clinically: Vital signs, Abdomino-pelvic examination, per-vaginal examination.

III. Laboratory: Hemoglobin, Hematocrit before & after cesarean section. IV. Routine Ultrasound. V. Cesarean section: done under spinal anathesia.

VI. Calculation of blood loss:

The quantity of blood loss (ml) is calculated from 3 components :

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • High risk women undergoing elective C-section
  • Hypertensive patients.
  • Obese patients.
  • Patients on LMWH.
  • Transverse lie
  • DM ( Type 1 & Gestational )
  • Cardiac ( Not on Anticoagulants )
  • Placenta Previa ( Not in PAS )
  • Previous uterine scar ( > previous 2 C- section )

排除标准

  • Patients with bleeding tendency.
  • HELLP Syndrome.
  • Emergency C- section.
  • Mechanical prosthetic valve
  • Atrial Fibrillation.
  • Allery to tranexamic acid
  • Placenta Accreta , Increta , percreata.

研究组 & 干预措施

preoperative

Experimental

1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) 30 mins before the operation

干预措施: Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) (Drug)

uterine incision

Experimental

1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) directly before uterine incision

干预措施: Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) (Drug)

结局指标

主要结局

Reduction of blood loss during C-section.

时间窗: 1 hour

ml

Prevention of 1ry postpartum hemorrhage.

时间窗: 24 hours

ml

次要结局

  • Reduction of hospital stay.(48 hours)
  • Decrease risk of maternal blood transfusion(48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ayman Hany, MD

Associate Professor

Cairo University

研究点 (1)

Loading locations...

相似试验